WWWeili Wang

Weili Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weili Wang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Rongrong Wang

    Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine

    3 shared publications
  • Tingbo Liang

    Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

    3 shared publications
  • Wei Zhang

    Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou China

    3 shared publications
  • Li Wang

    Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China

    2 shared publications
  • Pingbo Jin

    Zhejiang University School of Medicine

    2 shared publications
  • Xinyu Yu

    Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China

    2 shared publications

Latest Publications

  • Utility of Low‐Weight Grafts From Young Pediatric Donors in Children Liver Transplantation: Is There a Limit of Whole Graft Weight?

    by Zhiwei Li, Li Wang, Jie Xiang, Weili Wang, Wei Zhang

    Background: Low‐weight grafts from young pediatric donors are considered a risk factor for surgical complications. However, the limited availability of age‐ and size‐matched organs has prompted a re‐evaluation of low‐weight grafts from young pediatric donors. Methods: From January 1, 2019, to December 31, 2023, 52 pediatric liver transplants receiving young pediatric donors (≤ 2 years old) with low body weight (≤ 15 kg) were performed. According to graft weights (GW), recipients were divided into two groups: Group 1 (GW ≤ 150 g) and Group 2 (GW: 151–400 g), to compare donor and recipient characteristics, postoperative complications, and graft and recipient survival. Results: Group 1 donors were younger (5.4 ± 4.2 vs. 14.4 ± 4.7 months, p < 0.001), smaller in body length (58.0 ± 8.7 vs. 75.7 ± 8.5 cm, p < 0.001), and lighter in weight (6.2 ± 2.8 vs. 10.0 ± 2.0 kg, p < 0.001) compared to Group 2. There were no significant differences in preoperative laboratory tests between groups, and the incidences of vascular complications were also similar between the groups. The 1‐ and 3‐year patient survival rates were 100% and 100% in Group 1 vs. 97% and 97% in Group 2, respectively. The 1‐ and 3‐year graft survival rates were 100% and 91% in Group 1 vs. 97% and 97% in Group 2, with no significant differences. The smallest graft, weighing 86 g, yielded an ideal outcome for the recipient. Conclusions: Low‐weight grafts from young pediatric donors can achieve excellent outcomes and represent a potential strategy to increase donor availability for well‐selected pediatric recipients.


  • Open Access

    Comparison of Omicron and respiratory virus infections in pediatric liver transplantation: Impact of perioperative identification status

    by Pingbo Jin, Weili Wang, Wei Zhang, Xin Duan, Li Wang, Lei Zeng, Rongrong Wang, Xinyu Yu, Ying Chen, Yigang Qian, et al.

    Peri-operative respiratory virus (RV) infection is critical in paediatric liver transplantation. However, it has been inadequately studied, especially in terms of the clinical latency of infection (incubation period) and Omicron variant infection. Herein, we compared the infection profile of common RVs and Omicron variants in paediatric liver transplantation, aiming to identify the association of virus infection with outcomes. The Omicron cohort was designed prospectively, and the RV cohort was retrospective. Survival outcomes, medical resources, and major complications were compared. Risk factors associated with peri-operative mortality were investigated using regression analysis. We enrolled 649 paediatric liver transplantation patients, including 28 Omicron and 61 RV infections. The 1-y overall survival was 97.7 ± 0.6% for the non-infected group, and 93.4 ± 3.2% for the RV group (p = 0.092). No death occurred in the Omicron group. Mortality was higher in the clinical latency infection group compared with that in the non-infected group (13.8% vs. 1.4%, p = 0.002). Latent RV infection (hazard ratio (HR) = 6.323, 95% confidence interval (CI): 1.374-29.087), Multi‑drug resistance organism pneumonia (HR = 7.177, 95% CI: 1.817-28.350), infectious shock (HR = 4.284, 95% CI: 0.995-18.442) and blood loss (HR = 3.209, 95% CI: 1.166-8.833) were independent risk factors for peri-operative mortality. In conclusion, pre-transplant viral screening is fundamental to paediatric liver transplantation. Peri-operative Omicron infection might be controllable, while RV infection led to more complications compared with those in the non-infected group. Clinical latency infection is the key risk for paediatric liver transplantation mortality.

  • Open Access

    Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study

    by Rongrong Wang, Weili Wang, Kuifen Ma, Xin Duan, Fangfang Wang, Mingzhu Huang, Wei Zhang, Tingbo Liang

    Objective: High variabilities in tacrolimus (TAC) exposure are still problems that confuse physicians. TAC trough levels (TAC Cmin) fluctuated considerably after endoscopic retrograde cholangiopancreatography (ERCP) treatment in several liver transplant (LT) patients. We aimed to investigate the variation regularity of TAC Cmin post-ERCP and related factors. Methods: This study was a retrospective, observational study conducted at the First Affiliated Hospital of Zhejiang University in China. From October 2017 to January 2019, 26 LT patients that received ERCP were included (73 TAC Cmin measures). The absolute difference and the variation extent in TAC Cmin pre- and post-ERCP were analyzed. Patients were divided into mild and obvious variation groups, and the differences were compared. Results: The TAC Cmin in LT patients significantly increased in the first three days post-ERCP (p0.05). The daily TAC dose and total bile acid (TBA) level were significantly higher (pmin. The differences in other demographics, clinical characteristics, variation in laboratory data, and serum amylase levels between the two groups were not significant. Conclusion: The TAC Cmin significantly increased in LT patients during the first three days after ERCP, and the level returned to baseline within a week. The daily TAC dose and TBA levels may be related to this increase. Frequent drug concentration monitoring should be executed in the early phase post-ERCP, especially in patients with related factors.